Prohealth Research Center | Doral, FL

Research site

(Unclaimed)

Location

8247 Northwest 36th Street, Doral, Florida, United States of America

Site insights

Top conditions

Top treatments

Linaclotide

Methotrexate

Tenapanor

MTX

NOV-001

Ferric carboxymaltose

Ferrous Sulfate

Etrasimod

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 19 total trials

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegaloviru...

Enrolling

Cytomegalovirus

Biological: mRNA-1647

Other: Placebo

A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and...

Enrolling

Functional Constipation

Drug: Linaclotide

Drug: Placebo

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Functional constipation (FC) is a common healthcare problem in children of all ages, potentially due to genetic predisposition, inadequate fiber and...

Enrolling

Functional Constipation (FC)

Chronic Idiopathic Constipation (CIC)

Drug: Linaclotide

Drug: Placebo for Linaclotide

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Enrolling

SARS-CoV-2

Biological: mRNA-1273.815

Biological: mRNA-1273.214

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling

Gout

Drug: Methotrexate

Biological: Pegloticase

Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C

LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation...

Active, not recruiting

Functional Constipation

Irritable Bowel Syndrome With Constipation

Drug: Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)

Drug: Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 completers)

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling

Irritable Bowel Syndrome With Constipation (IBS-C)

Drug: Tenapanor 50 MG

Drug: Placebo

Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Eff...

Enrolling

Covid19

Drug: STRI Formula

Drug: Placebo